Proteomics International Laboratories (ASX:PIQ) said it has published study results showing its PromarkerEso blood test can diagnose Esophageal adenocarcinoma (EAC), the predominant form of esophageal cancer, with high accuracy, according to a Thursday filing with the Australian bourse.
The test showed accurately detected EAC, with over 91% sensitivity and about 99% specificity in a 147-person validation study, the filing said.
Shares of the company rose past 1% in recent Thursday trade.